Recap:
https://research.monash.edu/en/projects/evaluating-the-molecular-mechanisms-of-the-therapeutic-effects-of
2 March 2021
Dr. Kilian Kelly, Cynata’s Chief Operating Officer, said:
“This new study with Professor Samuel follows his earlier investigations, which confirmed the potent antiinflammatory and anti-fibrotic effects of our Cymerus MSCs in several different studies in pre-clinical models of allergic and fibrotic diseases of the lung, such as asthma and IPF. Given the importance of gaining a clearer understanding of the molecular processes involved in these potentially clinically useful effects, we believe this further study will provide important insights as we move forward in parallel with our plans for a clinical trial in IPF.”
7 September 2020
Professor Samuel commented:
“These results are extremely encouraging. While they are very consistent with our previous studies of these cells in a model of asthma, it was important to confirm that the potent anti-inflammatory and anti-fibrotic effects of Cymerus MSCs would be replicated in IPF, which is a disease with very different underlying pathophysiology. We look forward to publishing our results in a peer-reviewed journal in due course.”
https://files.cynata.com/613/200907CymerusMSCsEffectiveinPreclinicalLungDiseaseStudy.pdf
[...]
https://www.eurekalert.org/news-releases/936666
"We also found ubiquitous deposits of collagen, the main component of scar tissue."
It might be worthwhole also checking our first pre-clinical Asthma study here:
"IN delivery of Cymerus™ MSCs completely reversed pathologic collagen deposition in thelungs to levels seen in animals in which the asthma model was not induced. Pathologiccollagen deposition is a sign of airway remodelling/fibrosis. Previous studies by the samegroup found that IN administration of other types of stem cells did not have similar effects,unless used in combination with other drugs."
http://files.cynata.com/279/17.06.22.CYP-MSC-Data-in-Asthma-Model-Published-in-Scientific-Journal.pdf
I have summarised our Asthma studies here:
https://hotcopper.com.au/threads/ann-further-cynata-asthma-study-published.4649689/page-13?post_id=37560912
See here for my previous coverage on IPF/COVID-19:
https://hotcopper.com.au/threads/ann-ethics-approval-to-commence-clinical-trial-in-covid-19.5386633/page-180?post_id=45798738
Hopefully we get the final pre-clinical IPF study results ("Finished") soon!
- Forums
- ASX - By Stock
- CYP
- Ann: New Study to Investigate the High Potency of Cymerus MSCs
Ann: New Study to Investigate the High Potency of Cymerus MSCs, page-6
-
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CYP (ASX) to my watchlist
|
|||||
Last
19.0¢ |
Change
0.010(5.56%) |
Mkt cap ! $35.23M |
Open | High | Low | Value | Volume |
18.0¢ | 19.5¢ | 18.0¢ | $9.062K | 48.88K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 104632 | 18.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
19.0¢ | 3 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 104632 | 0.185 |
5 | 166488 | 0.180 |
1 | 285 | 0.175 |
2 | 4148 | 0.170 |
2 | 25050 | 0.165 |
Price($) | Vol. | No. |
---|---|---|
0.190 | 3 | 1 |
0.195 | 38853 | 1 |
0.200 | 25789 | 2 |
0.210 | 60000 | 1 |
0.250 | 16097 | 2 |
Last trade - 14.37pm 12/09/2024 (20 minute delay) ? |
Featured News
CYP (ASX) Chart |